Skip to main content
OpenTrials
Completed

NCT Number: NCT03140605

Greek Registry - Familial Hypercholesterolaemia

Familial hypercholesterolemia (FH) [heterozygous (heFH) or homozygous FH (hoFH)] is a common genetic disorder, characterized by elevated plasma low density lipoprotein (LDL) cholesterol concentration leading (if untreated) to cholesterol deposits in the corneas, eyelids and extensor tendons, rapidly progressing vascular disease, and aortic valve disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Familial Hypercholesterolemia Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dyslipidemias Genetic Diseases, Inborn Hyperlipidemias Hyperlipoproteinemia Type II Hyperlipoproteinemias Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Metabolic Diseases Metabolism, Inborn Errors Nutritional and Metabolic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Onassis Cardiology Hospital

Athens, Greece

About this study

In contrast, timely recognition and effective treatment of FH can result in a significant improvement in clinical outcomes. The problem is that that majority of individuals with FH are unaware of their disease, particularly that the disease remains silent for many years. In most countries around the world <5% of individuals with FH are identified .

Until lately the prevalence of heFH was traditionally considered to be ~ 1:500 individuals , although clinical and genetic studies suggest that heFH affects ~ 1:200-250 individuals . Thus, the aim of the Hellenic College of Treatment of Atherosclerosis (HCAT) is to 1). Evaluate the prevalence of FH in Greece (FHG-Registry) and 2). To inform population of FH disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • both genders
  • >18 years, <80 years
  • door to door enrolment
  • eligible to sign informed consent

Exclusion criteria

  • <18 years, >80 years
  • deny to sign informed consent

Treatment and study plan

Primary outcomes

  1. the prevalence of Familiar Hypercholesterolaemia in Greece

    Time frame: 1 month

    patients with FH will be screened and include in Registry

Sponsors and collaborators

Lead sponsor

Hellenic College of Treatment of Atherosclerosis

Other

Registry information

Official study title

Hellenic Registry for Familial Hypercholesterolemia

Acronym: GRegistry-FH

Important dates

Study start
2017
Primary completion
2022
Study completion
2022
First posted
May 4, 2017
Registry last updated
Jun 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.